



## SUPPLEMENTAL DATA



**Figure S1. ATM phosphorylation of Mdm2-S394 regulates Mdm2 levels and p53 activity in spleen, Related to Figure 1**


WT and *Mdm2*<sup>S394A</sup> mice were left untreated or exposed to 1.75 Gy ionizing radiation (IR) and whole spleens were harvested at 3 and 6 hours. Protein levels were analyzed by western blotting. TKO indicates *Mdm2*<sup>-/-</sup>, *MdmX*<sup>-/-</sup>, *p53*<sup>-/-</sup> control; Tg indicates *Mdm2*<sup>Tg/+</sup> Mdm2 overexpressing control.



**Figure S2. ATM phosphorylation of Mdm2-S394 impacts p53 destabilization after DNA damage, Related to Figure 2**


**(A)** Thymocytes harvested from WT and  $Mdm2^{S394A}$  mice ( $n = 6$ ) were treated with 100  $\mu$ g/ml cycloheximide and harvested at the indicated time points. The levels of p53 and  $\alpha$ -tubulin were analyzed by western blotting. Band intensities were determined by densitometry and p53 levels normalized to  $\alpha$ -tubulin were plotted. One-phase decay curves were fitted using GraphPad Prism software.

**(B)** Thymocytes harvested from WT and  $Mdm2^{S394A}$  mice ( $n = 6-8$ ) were exposed to 2.5 Gy IR before being treated with 100  $\mu$ g/ml cycloheximide and harvested at the indicated time points. The levels of p53 and  $\alpha$ -tubulin were analyzed by western blotting. Band intensities were determined by densitometry and p53 levels normalized to  $\alpha$ -tubulin were plotted. One-phase decay curves were fitted using GraphPad Prism software.




**Figure S3. Relative amounts of Mdm2-bound MdmX or p53-bound MdmX before or after DNA damage are not affected in *Mdm2*<sup>S394A</sup> mice, Related to Figure 2**

Whole thymus protein extracts were generated from mice that were untreated and 1 and 2 hours after exposure to 5 Gy IR. Protein extracts (500 µg) were immunoprecipitated with an antibody for MdmX (MDMX-82; Sigma). Immunoprecipitates were analyzed by western blotting for Mdm2 (NBP1-02158; Novus) and p53 (CM5; Novocastra). Total lysate (10% input) was analyzed by western blotting with antibodies for Mdm2, MdmX, p53, phospho-p53(S18), vinculin and α-tubulin.



**Figure S4. Immunohistochemical staining of representative tissue sections of IR-induced lymphomas, Related to Figure 4**

Higher magnification images of representative tissue sections of IR-induced lymphomas that developed in the thymus, spleen and liver of WT and *Mdm2*<sup>S394A</sup> mice stained with antibodies specific for CD3 (left) and B220 (right) as in Figure 4C. Scale bars represent 100  $\mu$ m.



**Figure S5. Colony-forming cell numbers in bone marrow before or after IR are not affected in *Mdm2*<sup>S394A</sup> mice, Related to Figure 6**

Total bone marrow was harvested from WT and *Mdm2*<sup>S394A</sup> mice that were left untreated, and 1 and 96 hours after exposure to 5 Gy IR. Colony-forming cell (CFC) assays (MethoCult 3434 and MethoCult 3630; StemCell Technologies) were carried out per manufacturer's instructions ( $n = 3-6, \pm$ SEM).

**Table S1. Antibodies Used for Flow Cytometry, Related to Figure 6**

Antibody	Clone	Fluorophore	Source
CD3	145-2C11	Biotin, APC	BD Bioscience
B220	RA3-6B2	Biotin, PE	BD Bioscience
Ter119	TER-119	Biotin	Biolegend
Gr-1	RB6-8C5	Biotin, APC, PE	Biolegend
Mac-1	M1/70	Biotin, FITC	Biolegend
Sca-1	D7	APC/Cy7	Biolegend
CD117	2B8	APC	BD Bioscience
CD34	RAM34	FITC	BD Bioscience
Fik2	A2F10	PE	Biolegend
CD45.2	104	FITC, PE/Cy7	Biolegend
CD45.1	A20	PercP/Cy5.5	Biolegend

## SUPPLEMENTAL EXPERIMENTAL PROCEDURES

### Protein Analysis

Tissues and cells were lysed in NP-40 lysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 0.5% NP-40) or in CellLytic MT Cell Lysis Reagent (Sigma), supplemented in both cases with protease and phosphatase inhibitor cocktail tablets (Roche). Protein extracts were analyzed by direct western blotting or immunoprecipitation/western blotting. Immunoprecipitations were performed on 500 µg whole thymus lysate with antibodies specific for Mdm2 (NBP1-02158; Novus (Ab-I) and Ab-5; Calbiochem (Ab-II)), p53 (CM5; Novocastra) and MdmX (MDMX-82; Sigma), using PureProteome Protein A/G Mix Magnetic Beads (Millipore). Mdm2 Ab-I immunoprecipitates were counterblotted with Mdm2 (Ab-5; Calbiochem (Ab-II)) and p53 (IMX25; Novocastra) antibodies. Mdm2 Ab-II immunoprecipitates were counterblotted with Mdm2 (NBP1-02158; Novus (Ab-I)) and p53 (CM5; Novocastra) antibodies. Western blotting was performed with antibodies specific for Mdm2 (NBP1-02158; Novus and Ab-5; Calbiochem), p53 (CM5; Novocastra), MdmX (MDMX-82; Sigma), p-ATM(S1981) (Cell Signaling), p-p53(S15) (#9284 or #12571; Cell Signaling), α-tubulin (B-5-1-2; Sigma), p21 (SXM30; BD Pharmingen), Puma (#7467; Cell Signaling), Arf (5-C3-1; Santa Cruz) and Cleaved Caspase-3(Asp175) (#9661; Cell Signaling). For cycloheximide experiments, single cell suspensions of thymocytes from 6-8 thymi were generated maintained in DMEM supplemented with 10% FBS. Thymocyte pools were untreated or irradiated with 2.5 Gy IR and immediately treated with cycloheximide (100 µg/ml; Sigma). Pools were aliquoted and maintained in a 37°C incubator with 5% CO<sub>2</sub> and collected for protein analysis at the indicated time points. Blots were imaged on a Chemidoc MP (Bio-Rad) and relative band intensities determined by densitometry using Image Lab software (v4.1, Bio-Rad).

### Gene Expression Analysis and Sequencing

Total RNA was isolated from tissues by RNeasy mini kit (QIAGEN) and cDNA synthesized by Superscript III First Strand Synthesis System (oligo-dT priming) (Invitrogen). Quantitative PCR was performed using SYBR Select Master Mix (Applied Biosystems) in conjunction with a 7300 Real-Time PCR System (Applied Biosystems). Thymus cDNA input was 10 ng and bone marrow cDNA input was 100 ng. Fold expression was calculated using the  $\Delta\Delta C_t$  method relative to untreated WT samples using *Rplp0* as internal reference. Primers used were as follows: *Puma*, 5'ACGACCTCAACGCGCAGTACG3' and 5'GAGGAGTCCCATGAAGAGATTG3'; *Noxa*, 5'CTCAGGAAGATCGGAGACAAAG3' and 5'GCACACTCGTCCTTCAAGT3'; *Bax*, 5'GTGGTTGCCCTTCTACTTT3' and 5'CAGCCCATGATGGTTCTGAT3'; *p21*, 5'CTGAGCGGCCTGAAGATT3' and 5'ATCTGCGCTTGGAGTGATAG3'; *Mdm2*, 5'AGTCTCTGGACTCGGAAGATTA3' and 5'CTGTATCGCTTTCCTGTCTG3'; *Rplp0*, 5'CTGAGTACACCTTCCCACCTTAC3' and 5'CTCTTCTTTCCTTTCAGCTTTG3'. *Arf* message was amplified from tumor sample cDNA using the following primer pair: 5'TCGCTTGTACAGTGAGG3' and 5'CCGATTTAGCTCTGCTCTT3'. p53 message was amplified from tumor sample cDNA in overlapping fragments using three separate primer pairs: p53seq1, 5'TTCATTGGGACCATCCTGGCTGTA3' and 5'AGGCACAAACACGAACCTCAAAGC3'; p53seq2, 5'CTTATCCGGGTGGAAGGAAAT3' and 5'GAAGTAGACTGGCCCTTCTTG3'; p53seq3, 5'AGCTTTGAGGTTCTGTTTGTGCC3' and 5'ATGCAGACAGGCTTGCAGAATGG3'. Amplified fragments were gel extracted (QIAGEN) and sequenced by Sequegen, Inc (Worcester, MA).